← feed

Is NCT03133234 results overdue?

Yes — results are overdue. Primary completion was 2017-09-13; the FDAAA-801 reporting deadline (2018-09-13) passed 2838 days ago and no results are posted on ClinicalTrials.gov.

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

NCT IDNCT03133234 ↗
SponsorAstraZeneca (INDUSTRY)
Public issuerASTRAZENECA PLC — AZN (CIK 0000901832) best-effort name match, 95% conf — verify on EDGAR ↗
Phase
StatusCOMPLETED
Primary completion2017-09-13 (ACTUAL)
Reporting deadline2018-09-13 (completion + 365d)
Days overdue2838
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 dc4a69bd28b61f17… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03133234. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →